Jens Bedke

26.7k citations

313 papers · 7.6k indexed · 7 hit papers · h-index 36

Impact in

Pulmonary and Respiratory Medicine top 0.5%
- Renal cell carcinoma treatment
- Ferroptosis and cancer prognosis
Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers

Papers in

Pulmonary and Respiratory Medicine 180
- Renal cell carcinoma treatment 125
- Prostate Cancer Treatment and Research 32
- Prostate Cancer Diagnosis and Treatment 27
Oncology 121
- Cancer Immunotherapy and Biomarkers 83

Co-authors: Arnulf Stenzl Stephan Kruck Jörg Hennenlotter Elizabeth R. Plimack Thomas Powles Steffen Rausch Bastian Amend Margitta Retz
Journals: Journal of Clinical Oncology (49 papers)World Journal of Urology (26 papers)Annals of Oncology (19 papers)British Journal of Urology (13 papers)European Urology (13 papers)
Partner nations: Germany United States United Kingdom

In The Last Decade

Jens Bedke

293 papers receiving 7.5k citations

Hit Papers

7 papers align trajectories log scale

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update 2025 · 18 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2025 European Urology
2023 Annals of Oncology
2022 The Lancet Oncology
2022 European Urology
2020 The Lancet Oncology
2017 The Lancet Oncology
2009 World Journal of Urology

Peers

Countries citing papers authored by Jens Bedke

Since Specialization

Citations

This map shows the geographic impact of Jens Bedke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jens Bedke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jens Bedke more than expected).

Fields of papers citing papers by Jens Bedke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jens Bedke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jens Bedke. The network helps show where Jens Bedke may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jens Bedke, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jens Bedke Line = papers co-authored together Jens Bedke links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study European Journal of Cancer ·Viktor Grünwald, Axel Bex, Sylvie Rottey, Verlain Doumtsop Tsoala, Giuseppe Procopio, Guillermo Velasco, Bohuslav Melichar, Jens Bedke, Lisa Pickering, Zharifta Kusuma Dewi, Manuela Schmidinger, Aristotelis Bamias, Marine Gross‐Goupil, Camillo Porta, Philippe Barthélémy, C. Marshall, Laurence Albigès	2025	1
2	Treatment of Advanced or Metastatic Urothelial Cancer Oncology Research and Treatment ·Ali Alkerata, Christopher Darr, Jens Bedke, Philipp Ivanyi, Niklas Klümper, Markus Eckstein, Katrin Schlack, Viktor Grünwald	2025	0
3	269O Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Pan-Asian subgroup analysis from EV-302/KEYNOTE-A39 Annals of Oncology ·Eiji Kikuchi, Michiel S. van der Heijden, Begoña P. Valderrama, Shilpa Gupta, Jens Bedke, Su‐Jin Shin, S. John Wort, J. Guo, Pongwut Danchaivijitr, Z. Strezova, Eric Snow Mr., Wen‐Pin Su, Kikuko HAMAGUCHI, Woo Kyun Bae, Alvin Wong, Jiaying Lu, Xuesong Yu, J.-L. Cui, Abhishek Bavle, Thomas Powles	2024	1
4	Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial. Journal of Clinical Oncology ·Matt D. Galsky, Guru Sonpavde, Thomas Powles, Mélanie Claps, Mauricio Burotto, Michael Schenker, Juan Pablo Sade, Aristotelis Bamias, Philippe Beuzeboc, Jens Bedke, Jan Oldenburg, Yüksel Ürün, Dingwei Ye, Begoña P. Valderrama, Yoshihiko Tomita, Jeiry Filian, Lily Wang, Daniela Purcea, Michiel Simon Van Der Heijden	2024	11
5	Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39. Journal of Clinical Oncology ·Michiel Simon Van Der Heijden, Shilpa Gupta, Jens Bedke, Begoña P. Valderrama, Eiji Kikuchi, Gopa Iyer, Yohann Loriot, Nancy A. Dawson, Jean Hoffman‐Censits, Nataliya Mar, Srikala S. Sridhar, Qi Peng, Sang Joon Shin, Evan Y. Yu, Ignacio Durán, Xi Xi, Xuesong Yu, Aditya Shetty, Abhishek Bavle, Thomas Powles	2024	3
6	Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial ESMO Open ·Thomas Powles, Mauricio Burotto, Bernard Escudier, Andrea B. Apolo, María T. Bourlon, Amishi Y. Shah, Cristina Suárez, Camillo Porta, Carlos H. Barrios, Martin Eduardo Richardet, Howard Gurney, Elizabeth R. Kessler, Yoshihiko Tomita, Jens Bedke, Saby George, Christian Scheffold, Diego Fernando González Lozano, 中田和直, Robert J. Motzer, Toni K. Choueiri	2024	31
7	LBA7 Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial Annals of Oncology ·Michiel S. van der Heijden, Guru Sonpavde, Thomas Powles, Andrea Necchi, Mauricio Burotto, Michael Schenker, B.H. Viana Montanera, Aristotelis Bamias, Philippe Beuzeboc, Jens Bedke, Jan Oldenburg, Joe Young, X. Dong, Zhisong He, Begoña P. Valderrama, 立教大学フランス語フランス文学研究室, Adekunle Sanyaolu, Daniela Purcea, Federico Nasroulah, Matt D. Galsky	2023	9
8	Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and Metastases International Journal of Molecular Sciences ·Moritz Maas, D.W. McFadyen, Jörg Hennenlotter, Marcus Scharpf, Falko Fend, Simon Walz, Viktoria Stühler, Tilman Todenhöfer, Arnulf Stenzl, Jens Bedke, Steffen Rausch	2023	2
9	211MO EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC) Annals of Oncology ·Thomas Powles, Begoña P. Valderrama, Shilpa Gupta, Jens Bedke, Eiji Kikuchi, Jean Hoffman‐Censits, Gopa Iyer, Christof Vulsteke, Jun-Jun Zhu, Sang Joon Shin, Tomasz Kossak, Giuseppe Fornarini, S. John Wort, (unknown), Nataliya Mar, Kenneth B. Haas, Xin Yu, Seema Rao Gorla, Blanca Homet Moreno, Michiel S. van der Heijden	2023	1
10	Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial European Urology Oncology ·Brian I. Rini, Michael B. Atkins, Elizabeth R. Plimack, Denis Soulières, Ray McDermott, Jens Bedke, Sophie Tartas, B. Yа. Alekseev, Bohuslav Melichar, Yaroslav Shparyk, Chihiro Kondoh, 文理辰野, Lori Wood, Hans J. Hammers, Lina S. Morón-Duarte, Barbara Haber, Erin Jensen, Mei Chen, Thomas Powles	2021	25
11	On the probability of lymph node negativity in pN0-staged prostate cancer—a theoretically derived rule of thumb for adjuvant needs Strahlentherapie und Onkologie ·Frank Paulsen, Jens Bedke, Barbara L Nye, Xue Yong-sheng, Peter Martus, Dominik Nann, Arnulf Stenzl, Daniel Zips, Arndt‐Christian Müller	2021	1
12	Real world data on the use of nivolumab and ipilimumab combination therapy or nivolumab monotherapy in the treatment of renal cell carcinoma: Interim results from the non-interventional study (NIS) NORA European Urology Open Science ·Marc‐Oliver Grimm, Viktor Grünwald, L. Bontemps, D A Kelly, Sophia Khan, Jens Bedke	2020	1
13	Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial European Urology ·Brian I. Rini, Robert J. Motzer, Thomas Powles, David F. McDermott, Bernard Escudier, Frede Donskov, Robert D. Hawkins, Sergio Bracarda, Jens Bedke, Ugo De Giorgi, Camillo Porta, Alain Ravaud, Francis Parnis, Enrique Grande, Wei Zhang, Mahrukh Huseni, Susheela Carroll, Roxana I. Sufan, Christina Schiff, Michael B. Atkins	2020	60
14	PD-1 and LAG-3 Dominate Checkpoint Receptor–Mediated T-cell Inhibition in Renal Cell Carcinoma Cancer Immunology Research ·Henning Zelba, Jens Bedke, Jörg Hennenlotter, Sven Mostböck, Markus Zettl, Thomas Zichner, Anoop Chandran, Arnulf Stenzl, Hans‐Georg Rammensee, Cécile Gouttefangeas	2019	78
15	Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC) Annals of Oncology ·Laurence Albigès, Brian I. Rini, John B.A.G. Haanen, Robert J. Motzer, C. Kollmannsberger, Sylvie Négrier, Franco Nolè, Jens Bedke, Mehmet Asım Bilen, Paul Nathan, Yoshihiko Tomita, Bin Huang, Keith A. Ching, A. Chudnovsky, Paul B. Robbins, Alessandra di Pietro, Despina Thomaidou, Toni K. Choueiri	2019	16
16	Molecular Signatures of Primary Human Spermatogonial Progenitors and Its Neighboring Peritubular Stromal Compartment Stem Cells and Development ·Abhishek Harichandan, K. Sivasubramaniyan, Jörg Hennenlotter, Sven Poths, Jens Bedke, Stephan Kruck, Arnulf Stenzl, Hans‐Jörg Bühring	2016	3
17	Investigation to Restore Innervation of the Lower Urinary Tract of Spinal Cord Injured Patients: A European Single-Center Retrospective Study with Long-term Follow-up Neurourology and Urodynamics ·Karl‐Dietrich Sievert, Bastian Amend, Florian Röser, Andreas Badke, D’Angelo Robert, Marzena Gwadera, Patricia Toomey, Jens Bedke, Stephan Kruck, عبدالفتاح الطاهري, Arnulf Stenzl, Минникова Т. В.	2014	1
18	DNA Methylation of the SLC16A3 Promoter Regulates Expression of the Human Lactate Transporter MCT4 in Renal Cancer with Consequences for Clinical Outcome Clinical Cancer Research ·Pascale Fisel, Stephan Kruck, Stefan Winter, Jens Bedke, Jörg Hennenlotter, Anne T. Nies, Marcus Scharpf, Falko Fend, Arnulf Stenzl, Matthias Schwab, Elke Schaeffeler	2013	79
19	Cisplatin Hypersensitivity of Testicular Germ Cell Tumors Is Determined by High Constitutive Noxa Levels Mediated by Oct-4 Cancer Research ·Matthias Gutekunst, Thomas Mueller, Tsuyoshi Itokawa, Michael A. Dengler, Jens Bedke, Stephan Kruck, Moshe Oren, Walter E. Aulitzky, Heiko van der Kuip	2013	47
20	Nierenzellkarzinom : Neue Entwicklungen in Diagnostik und Therapie (Übersichten) Urologe A ·Jens Bedke, Arnulf Stenzl	2010	2

About Jens Bedke

Jens Bedke is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Urology and Surgery, having authored 313 papers that have together received 7.6k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (125 papers), Cancer Immunotherapy and Biomarkers (83 papers), Bladder and Urothelial Cancer Treatments (83 papers), Renal and related cancers (56 papers), Cancer Genomics and Diagnostics (42 papers), Urinary and Genital Oncology Studies (42 papers), Prostate Cancer Treatment and Research (32 papers) and Prostate Cancer Diagnosis and Treatment (27 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (3.9k citations), Oncology (3.0k citations), Cancer Research (1.4k citations), Surgery (2.8k citations) and Urology (333 citations). Jens Bedke has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Arnulf Stenzl, Stephan Kruck, Jörg Hennenlotter, Elizabeth R. Plimack, Thomas Powles, Steffen Rausch, Bastian Amend, Margitta Retz, Andrea Necchi and Sergio Bracarda. Their work appears in journals such as Journal of Clinical Oncology, World Journal of Urology, Annals of Oncology, British Journal of Urology and European Urology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact